abstract |
The present invention relates to substituted dihydroimidazolones in the treatment of canine epilepsy, especially [1- (4-chlorophenyl) -4- (4-morpholinyl) -2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or the use of physiologically acceptable salts thereof. |